Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Study on the Diagnostic Value of Novel PET Molecular Imaging for Renal Cell Carcinoma
NCT07301827Recruiting
- Start
- Jun 2025
- Primary completion
- May 2026
- Modality
- Antibody Fragments, Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Open-label trial of [68Ga]Ga-DOTA-CAIX peptide, [68Ga]Ga-PSMA and [68Ga]Ga-NOTA-CD70 antibody fragment in renal cell carcinoma (RCC) (3 arms). Primary endpoint: Visual and standardized uptake values assessment of lesions and biodistribution at 1 year. Started Jun 2025; status: recruiting.
02
Drugs
[68Ga]Ga-DOTA-CAIX peptide[68Ga]Ga-PSMA[68Ga]Ga-NOTA-CD70 antibody fragment
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT07301827.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07301827.